Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · IEX Real-Time Price · USD
36.35
+1.78 (5.15%)
Mar 28, 2024, 4:00 PM EDT - Market closed
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for TARS stock have an average target of 48.17, with a low estimate of 30 and a high estimate of 59. The average target predicts an increase of 32.52% from the current stock price of 36.35.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TARS stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
Buy | 1 | 1 | 1 | 1 | 2 | 2 |
Hold | 0 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 4 | 4 | 4 | 5 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Jefferies | Jefferies | Strong Buy Maintains $30 → $44 | Strong Buy | Maintains | $30 → $44 | +21.05% | Mar 6, 2024 |
Goldman Sachs | Goldman Sachs | Hold Maintains $19 → $30 | Hold | Maintains | $19 → $30 | -17.47% | Feb 29, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $57 | Strong Buy | Maintains | $50 → $57 | +56.81% | Feb 28, 2024 |
Barclays | Barclays | Buy Maintains $40 → $50 | Buy | Maintains | $40 → $50 | +37.55% | Feb 28, 2024 |
Oppenheimer | Oppenheimer | Buy Reiterates $55 → $59 | Buy | Reiterates | $55 → $59 | +62.31% | Feb 28, 2024 |
Financial Forecast
Revenue This Year
90.75M
from 17.45M
Increased by 420.15%
Revenue Next Year
187.23M
from 90.75M
Increased by 106.31%
EPS This Year
-4.51
from -4.62
EPS Next Year
-2.28
from -4.51
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 111.4M | 237.8M | 420.0M | 474.9M | 570.7M |
Avg | 90.8M | 187.2M | 329.8M | 400.6M | 522.8M |
Low | 47.7M | 115.6M | 184.2M | 304.8M | 459.6M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 538.4% | 162.1% | 124.3% | 44.0% | 42.5% |
Avg | 420.2% | 106.3% | 76.1% | 21.5% | 30.5% |
Low | 173.4% | 27.4% | -1.6% | -7.6% | 14.7% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -3.70 | -0.37 | 2.50 | -0.46 | 1.96 |
Avg | -4.51 | -2.28 | 0.79 | -0.45 | 1.91 |
Low | -5.33 | -4.17 | -3.14 | -0.43 | 1.83 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.